• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

liver disease - Articles and news items

FDA grants fast track for Shire’s NASH investigational treatment

FDA grants fast track for Shire’s NASH investigational treatment

Industry news / 29 July 2016 / Mandy Parrett, Editorial Assistant

Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +